Vivace Therapeutics Announces Receipt of Orphan Drug Designation for VT3989 for Treatment of Mesothelioma
Potential Best-in-Class TEAD Autopalmitoylation Inhibitor Supported by Promising Clinical Data SAN MATEO, Calif., July 30, 2025 /PRNewswire/ — Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class …